BCOP Self-Study
These modules focus on literature published within the last two years. Participants will learn about new developments and cutting-edge findings through case-based discussions that help you apply the information presented.
Self-Study 2025 Release II is now available - it contains 11 ACPE and BCOP CEs total.
Learning Opportunities
-
BundleLearn more
Self-Study 2025 Release II Bundle
On-demand The 2025 BCOP Self-Study Bundle Release II offers 11 BCOP CE hours and ACPE CE hours. -
IndividualLearn more
Self-Study 2025 Release II: Review of CNS Prophylaxis in Hematologic Malignancies
On-demand At the end of this self-study course, you will have the tools to administer preventative CNS-directed therapy that balances efficacy and toxicity with the patient's overall goals of care. -
IndividualLearn more
Self-Study 2025 Release II: Gene Therapy Advances in Hemophilia, Sickle Cell Disease, and Beta-Thalassemia
On-demand In this module, we will explore the different mechanisms of action of available agents and their varied impact on target diseases. Readers will also consider the challenges to incorporating gene therapies into routine care of individuals with hemophilia, sickle cell disease, and beta-thalassemia. -
IndividualLearn more
Self-Study 2025 Release II: The Four Body Problem: Four Drug Regimens in Newly Diagnosed Multiple Myeloma
On-demand This module will review the safety and efficacy of four-drug regimens for the treatment of newly diagnosed multiple myeloma. -
IndividualLearn more
Self-Study 2025 Release II: Updates in the Treatment of Hormone Receptor-Positive (HR+) Metastatic Breast Cancer
On-demand In this module, participants will evaluate the recent data behind imlunestrant, inavolisib, trastuzumab deruxtecan, and datopotamab deruxtecan and explore the clinical situations in which the utilization of these agents would be appropriate. -
IndividualLearn more
Self-Study 2025 Release II: Antibody Drug Conjugates (ADCs) in Solid Tumors
On-demand This module will provide an overview of ADCs structure, including monoclonal antibody, linker, and cytotoxic agent, while also briefly discussing key factors that impact ADC toxicity profiles.